Investor Watch | Gracell Cell Therapy for Multiple Myeloma Granted FDA Orphan Drug Status

Join The Conversation! | https://trialsitenews.com/
Founded by Chinese biotech entrepreneur Wei William Cao, Suzhou, China headquartered Gracell Biotechnologies Co., Ltd (Gracell) is on a mission to bring best-in-class and economical cellular medicines to cancer patients. Dedicating capital, talent, and technology to resolve the cellular gene therapy industry’s major challenges including high production costs, lengthy manufacturing process, lack of off-the-shelf products, and short duration of therapeutic effects, the global clinical-stage biopharmaceutical company leverages its pioneering FastCAR and TruUCAR technology platforms. The company recently reported good news: its investigational treatment for multiple myeloma known as GCO12F has been assigned orphan drug status by the U.S. Food and Drug Administration (FDA).